Overview
The GLP-1 receptor agonist class of peptides has generated significant interest in metabolic research. Two of the most studied compounds are Semaglutide and Retatrutide — available in our Weight Loss & Metabolic Research category.
Semaglutide
Semaglutide is a GLP-1 receptor agonist. It shares approximately 94% sequence homology with native human GLP-1 but has been structurally modified for extended half-life through:
- C18 fatty diacid chain attached via a linker to lysine at position 26
- Two amino acid substitutions (Aib at position 8, arginine at position 34)
These modifications extend its half-life to approximately 7 days, making it valuable for sustained-exposure research models.
Retatrutide
Retatrutide (LY3437943) is a triple agonist targeting GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This multi-receptor activity profile distinguishes it from mono-agonist compounds.
Key structural features:
- C20 fatty diacid via two-step linker
- Modified GLP-1 backbone with glucagon and GIP receptor binding optimisation
- Extended half-life designed for once-weekly dosing in clinical models
Receptor Profile Comparison
| Property | Semaglutide | Retatrutide |
|---|---|---|
| GLP-1 receptor | ✓ | ✓ |
| GIP receptor | ✗ | ✓ |
| Glucagon receptor | ✗ | ✓ |
| Approximate half-life | ~7 days | ~6 days |
Choosing for Research
The choice between these compounds depends entirely on the research question. Semaglutide provides a well-characterised GLP-1 monoagonist model, while Retatrutide enables study of combined incretin and glucagon receptor interactions.
Browse our full metabolic research peptide range for available compounds and current stock.
All products are sold for research and laboratory purposes only. Not intended for human consumption.